Imagen de Portada

Factors Associated With Motivation to Reduce Alcohol Use Among Patients With Chronic Liver Disease

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Derek D. Satre, Dhweeja Dasarathy, Steven L. Batki, Michael J. Ostacher, Hannah R. Snyder, William Hua, Priti Parekh, Amy M. Shui, Ramsey Cheung, Alexander Monto, Robert J. Wong, Jennifer Y. Chen, Meimei Liao, Michele Tana, Po‐Hung Chen, Christina G. Haight, Taylor Fakadej, Mandana Khalili
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Alimentary Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Impact of GLP‐1 Receptor Agonists on Alcohol‐Related Liver Disease Development and Progression in Alcohol Use Disorder
por: Chia‐Chih Kuo, et al.
Publicado: (2025)

Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States
por: Pojsakorn Danpanichkul, et al.
Publicado: (2025)

Waitlist and Post‐Transplant Outcomes in Liver Transplantation for Alcohol‐Associated Liver Disease: An Individual Patient Data Meta‐Analysis
por: Glenn Jun Kit Ho, et al.
Publicado: (2025)

Differential Characteristics and Survival Outcomes of Patients With Cirrhosis According to Underlying Liver Aetiology
por: Yu Shi, et al.
Publicado: (2025)

Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease
por: Luis Antonio Díaz, et al.
Publicado: (2025)

Editorial: Balancing the Yin and Yang of Alcohol‐Associated Liver Disease—Integrating Pathophysiology, Liver‐Directed Therapy and Addiction Management
por: Raj Vuppalanchi, et al.
Publicado: (2025)

Letter: Safety and Tolerability of Injectable Extended Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease
por: Xing Bai, et al.
Publicado: (2025)

Disparities in Alcohol‐Associated Liver Disease Hospital Encounters Amongst a Texas‐Based Cohort of Patients
por: Thomas G. Cotter, et al.
Publicado: (2025)

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions
por: Xinglin Li, et al.
Publicado: (2026)

Letter: Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease—Authors' Reply
por: Luis Antonio Díaz, et al.
Publicado: (2025)

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis
por: Yee Hui Yeo, et al.
Publicado: (2026)

Editorial: Two Common Risks, One Greater Harm—Diabetes and Alcohol in Steatotic Liver Disease
por: Stine Johansen, et al.
Publicado: (2026)

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions. Authors' Reply
por: Ryan Yanzhe Lim, et al.
Publicado: (2026)

Late Diagnosis of Chronic Hepatitis B in the United States: A Population‐Based, Retrospective Cohort Study From 2007 to 2021
por: Michael H. Le, et al.
Publicado: (2025)

Editorial: Liver and Non‐Liver Outcomes Between Different Subtypes of Steatotic Liver Disease
por: Jee‐Fu Huang, et al.
Publicado: (2026)

Editorial: Navigating the Beta‐Blocker Dilemma in Advanced Liver Cirrhosis—When Is the Right Time to Discontinue?
por: Louise J. M. Alferink, et al.
Publicado: (2024)

Disordered Bile Acid Metabolism in Alcohol‐Related Hepatitis
por: Luke D. Tyson, et al.
Publicado: (2026)

Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non‐Liver Malignancies in Hepatitis B Endemic Areas
por: Yi‐Ping Hung, et al.
Publicado: (2024)

Steatotic Liver Disease Prevalence in China: A Population‐Based Study and Meta‐Analysis of 17.4 Million Individuals
por: Zhenqiu Liu, et al.
Publicado: (2025)

Letter: Post‐HCV Cure, Precision Assessment of Liver Stiffness and Diabetes Risk in Maternal Populations—A Critical Research Need
por: Zihe Guan, et al.
Publicado: (2025)

Diagnostic Impact of Liver Biopsy Among Antinuclear Antibody Positive Individuals With Mild Liver Enzyme Elevation
por: David Mehdi Asgher Niazi, et al.
Publicado: (2026)

Editorial: Steatotic Liver Diseases Emerge as Rapidly Growing Drivers of Primary Liver Cancer in the United States
por: Kelly Torosian, et al.
Publicado: (2025)

Editorial: Cephalosporin‐Induced Liver Injury—Interesting but Tricky. Authors' Reply
por: Raj Vuppalanchi, et al.
Publicado: (2025)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’. Authors' Reply
por: Christian Labenz, et al.
Publicado: (2026)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis
por: Ewan Forrest, et al.
Publicado: (2025)

Increased Risk for Liver Disease in Patients With Chronic Hepatitis B Virus Infection and Low‐Level Viraemia
por: Paul Y. Kwo, et al.
Publicado: (2026)

Subtype Differences in Major Adverse Liver Outcomes and Cardiovascular Events and Mortality in Steatotic Liver Disease: A UK Biobank Analysis
por: Takao Miwa, et al.
Publicado: (2026)

Editorial: Metabolic Dysfunction and Alcohol—Two Sides of the Same Coin
por: Gustavo Ayares, et al.
Publicado: (2024)

Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral Eradication
por: Pei‐Chien Tsai, et al.
Publicado: (2025)

Persistent Binge Drinking History Associated With Advanced Liver Fibrosis and All‐Cause Mortality in MetALD
por: Zhe‐Kun Xiong, et al.
Publicado: (2025)

Clinical Trial: Semaglutide Versus Placebo in NIT ‐Assessed MASH —A Multicenter Randomised Placebo‐Controlled Trial ( SAMARA )
por: Veeral Ajmera, et al.
Publicado: (2026)

Editorial: The Role of Liver Biopsy in ANA Positive Subjects
por: Einar S. Björnsson
Publicado: (2026)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol
por: Karen Cheuk‐Ying Ho, et al.
Publicado: (2025)

Editorial: Cephalosporin‐Induced Liver Injury—Interesting but Tricky
por: Einar S. Björnsson
Publicado: (2025)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis—Authors' Reply
por: Francisco Idalsoaga, et al.
Publicado: (2025)

Letter on ‘Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD )’; Authors’ reply
por: Kaleb Tesfai, et al.
Publicado: (2026)

Editorial: An Important Step Towards Mastering Metabolic Dysfunction‐Associated Steatohepatitis‐Targeted Therapy in Diabetes
por: Johnny Yau‐Cheung Chang, et al.
Publicado: (2025)

Liver Fibrosis and the Risk of Coronary Artery Disease, Stent Thrombosis, Restenosis and Adverse Clinical Outcomes
por: Na Tian, et al.
Publicado: (2025)

Letter: Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Related Liver Cancer—Results From the Global Burden of Disease Study 2021
por: Chunlong Liu, et al.
Publicado: (2025)

Letter: The Prognostic Role of IGF‐1 in Chronic Liver Disease
por: Muhammad Osama, et al.
Publicado: (2024)